Perspective Therapeutics (NYSE: CATX) highlights new 212Pb trial data at 2026 ASCO
Perspective Therapeutics announced interim clinical results for its three 212Pb radiopharmaceutical programs which will be presented at the 2026 ASCO meeting. The data shows promising safety profiles with no dose-limiting toxicities across neuroendocrine tumors, metastatic melanoma, and FAP-positive solid tumors, alongside early signs of antitumor activity. The company plans to release further data updates in late 2026.
Early melanoma trial sees tumor responses in hard-to-treat patients
Perspective Therapeutics announced updated data from its clinical programs, including [212Pb]VMT01 for melanoma, highlighting two confirmed responses out of seven heavily pre-treated patients (29% response rate) in its 3.0 mCi monotherapy cohort. The company is also advancing [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for FAP-expressing solid tumors, with further data to be presented at the 2026 ASCO Annual Meeting. All three programs have demonstrated favorable safety profiles, with no dose-limiting toxicities reported.
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation
UBS has reiterated its Buy recommendation for Perspective Therapeutics (CATX). This continued endorsement by a major financial institution suggests a positive outlook on the company's stock performance. Investors and market watchers may view this as a signal of confidence in CATX's future prospects.
UBS Maintains Perspective Therapeutics (CATX) Buy Recommendation
UBS has reaffirmed its Buy rating on Perspective Therapeutics (CATX). The financial services firm has also maintained its price target for CATX. This indicates continued confidence in the company's stock performance.
Perspective Therapeutics doses first patients in two trial cohorts
Perspective Therapeutics (CATX) has begun dosing patients in two new cohorts for its Phase 1/2a clinical trials, using its radiopharmaceutical treatments [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for solid tumors. The company is valued at $439 million and has seen its stock rise by nearly 69% in the past six months, though it faces negative free cash flow. RBC Capital, H.C. Wainwright, Jones Trading, and Truist Securities have maintained positive ratings on the stock, with price targets ranging from $12 to $18, anticipating further data releases later in the year.
Perspective Therapeutics, Inc. Initiates Patient Dosing in Phase 1/2a Studies for [212Pb]VMT-α-NET and [212Pb]PSV359 in Neuroendocrine and Solid Tumors
Perspective Therapeutics, Inc. has begun dosing patients in Phase 1/2a clinical studies for two radiopharmaceuticals, [212Pb]VMT-α-NET and [212Pb]PSV359, targeting neuroendocrine and solid tumors, respectively. The studies aim to assess the safety and efficacy of these alpha-emitting isotopes. The company is using a "theranostic" approach to personalize cancer treatment, with ongoing expansion of clinical programs and manufacturing capabilities.
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
Perspective Therapeutics has announced the first patients have been dosed in new cohorts of two ongoing Phase 1/2a studies. These studies involve [212Pb]VMT-α-NET for neuroendocrine tumors and [212Pb]PSV359 for solid tumors. The company is exploring optimized dosing regimens to improve response rates and tolerability while assessing safety and preliminary anti-tumor activity.
Two cancer radiopharmaceuticals start dosing patients in early trials
Perspective Therapeutics (NYSE American: CATX) announced the dosing of the first patients in new cohorts for two Phase 1/2a studies involving cancer radiopharmaceuticals. One study focuses on [212Pb]VMT-α-NET for SSTR2+ neuroendocrine tumors, exploring a front-loaded 20 mCi regimen. The other is for [212Pb]PSV359 in FAP-α–expressing solid tumors, with patients receiving up to four 6.0 mCi doses every eight weeks following a safety review.
Morgan Stanley lists shared 2.6% stake in Perspective Therapeutics (CATX)
Morgan Stanley has filed an amendment to its Schedule 13G for Perspective Therapeutics (CATX), reporting a shared voting power of 2,930,734 shares and a shared dispositive power of 2,959,296 shares, amounting to a 2.6% stake in the company. The filing, dated May 12, 2026, explicitly states that Morgan Stanley has ceased to be the beneficial owner of more than five percent of CATX's securities. This indicates a reduction in their ownership interest below the 5% threshold required for certain reporting categories.
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics announced its business highlights and financial results for the first quarter of 2026, showcasing advancements in its clinical programs for neuroendocrine tumors, melanoma, and FAP-positive solid tumors. The company reported a strong financial position with approximately $271 million in cash, cash equivalents, and short-term investments as of March 31, 2026, projecting a cash runway into late 2027. Key developments include regulatory engagement expected for its lead program, VMT-α-NET, and progress in expanding manufacturing infrastructure, including the near completion of its Chicago facility.
Working capital per share of Perspective Therapeutics, Inc. – FWB:AAJ0
The article focuses on the working capital per share of Perspective Therapeutics, Inc. (FWB:AAJ0) as listed on the Frankfurt Stock Exchange. It provides context for financial analysis within the healthcare technology sector. The information is presented by TradingView, sourcing data from ICE Data Services, FactSet, and Quartr for SEC filings.
Perspective Therapeutics (NYSE: CATX) posts Q1 loss, cash runway to late 2027
Perspective Therapeutics reported a net loss of $26.2 million for Q1 2026 but bolstered its cash reserves to $271 million following a $164 million underwritten offering in February. This financial position is expected to fund operations and clinical milestones through late 2027. The company is advancing three clinical-stage radiopharmaceutical programs and expanding its manufacturing capabilities, including a facility in Chicago set for completion in 2026.
Perspective Therapeutics 1Q Loss/Shr 25c >CATX
Perspective Therapeutics announced a first-quarter loss per share of 25 cents. Further financial details are expected to be provided in their official earnings report. This report is identified by the stock symbol CATX.
Perspective Therapeutics: Q1 Earnings Snapshot
Perspective Therapeutics (CATX) reported a first-quarter loss of $26.2 million, translating to a loss of 25 cents per share. This performance exceeded Wall Street expectations, which had predicted a loss of 29 cents per share. The company, an isotope-based medical products maker, recorded revenue of $76,000 for the period.
Perspective Therapeutics: Q1 Earnings Snapshot
Perspective Therapeutics (CATX) reported a first-quarter loss of $26.2 million, or 25 cents per share, which was better than the 29 cents per share loss anticipated by analysts. The Seattle-based medical products maker generated $76,000 in revenue during the period. These results were generated by Automated Insights using data from Zacks Investment Research.
Is Perspective Therapeutics (CATX) Attractively Valued After Q1 2026 Earnings With EPS -0.25 Beating -0.31 and Revenue $0.08M Missing $0.14M?
Perspective Therapeutics (CATX) reported Q1 2026 GAAP EPS of -$0.25, beating estimates of -$0.31, though grant revenue of $0.08 million missed the estimated $0.14 million. The company strengthened its financial position with a February 2026 offering, increasing cash and short-term investments to $271 million, which supported accelerated R&D investments in its clinical programs. Despite progress in clinical trials and a solid balance sheet, CATX faces challenges common to early-stage radiopharmaceutical developers, including limited revenue generation and widening operating losses, with its GF Value currently not available and a GF Score of 39/100.
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Perspective Therapeutics, Inc. announced its earnings results for the first quarter ended March 31, 2026. The company reported a net loss of USD 26.19 million, an increase from USD 18.18 million in the prior year. Basic and diluted loss per share from continuing operations remained constant at USD 0.25 compared to the previous year.
Perspective Therapeutics: $271M cash to advance 3 cancer trials
Perspective Therapeutics (NYSE American: CATX) reported Q1 2026 results, highlighting $271 million in cash, equivalents, and short-term investments, which is expected to fund operations into late 2027. The company is advancing three clinical-stage 212Pb radiopharmaceutical programs (VMT-α-NET, VMT01, PSV359) with multiple data milestones anticipated in 2026, alongside expanding its manufacturing network. Despite an increase in R&D expenses and a wider net loss, a February underwritten offering provided $164 million in net proceeds, strengthening its financial position.
[10-Q] Perspective Therapeutics, Inc. Quarterly Earnings Report
Perspective Therapeutics, Inc. (CATX) reported a net loss of $26.2 million for Q1 2026, widening from $18.2 million a year prior, primarily due to increased research and development expenses as it advances its radiopharmaceutical pipeline. The company's cash and short-term investments totaled $270.9 million, bolstered by a $175.0 million offering in February 2026, which management expects to fund operations and clinical milestones into late 2027. Key clinical programs, including VMT-α-NET, VMT01, and PSV359, are progressing through Phase 1/2a trials, with ongoing investments in manufacturing infrastructure to support future commercial-scale production.
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
Perspective Therapeutics announced its business highlights and financial results for the first quarter of 2026. The company is advancing three clinical-stage oncology programs and expects multiple clinical catalysts throughout 2026. Financially, the company reported approximately $271 million in cash, cash equivalents, and short-term investments as of March 31, 2026, with a cash runway expected into late 2027.
Perspective Therapeutics: Q1 Earnings Snapshot
Perspective Therapeutics (CATX) reported a first-quarter loss of $26.2 million, or 25 cents per share, outperforming Wall Street expectations. Analysts had projected a loss of 29 cents per share for the Seattle-based medical products maker. The company recorded revenue of $76,000 for the period.
Perspective Therapeutics: Q1 Earnings Snapshot
Perspective Therapeutics (CATX) reported a first-quarter loss of $26.2 million, or 25 cents per share, which surpassed Wall Street expectations of a 29 cents per share loss. The Seattle-based isotope-based medical products maker also declared revenue of $76,000 for the period.
Number of shareholders of Perspective Therapeutics, Inc. – AMEX:CATX
This article provides details on Perspective Therapeutics, Inc. (AMEX: CATX), listing it on NYSE American. It appears to be a stub or a section of a larger financial data page, giving an overview of the company's financial information, technical analysis, forecasts, and community discussions. The article also mentions the various data sources used for financial and reference data.
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript
This article provides the transcript of Perspective Therapeutics Inc's presentation at the JPMorgan Healthcare Conference on January 14, 2026. The company's team, including Tay Boer, Joel S. Sendek, and Marcus Pullman, presented, followed by a Q&A session. The event was introduced by Ben Davis from JPMorgan Healthcare Investment Banking.
Perspective Therapeutics (NYSEAM:CATX) - Stock Analysis
This report provides a detailed stock analysis of Perspective Therapeutics (NYSEAM:CATX), a radiopharmaceutical development company. It highlights that the company is currently valued at US$435.5m, is unprofitable, and is not forecasted to become profitable within the next three years, with revenue expected to grow significantly. The analysis covers historical performance, financial health, recent announcements, and insider transactions, noting risks such as substantial shareholder dilution and share price volatility.
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18
JonesTrading has reiterated its Buy rating for Perspective Therapeutics (CATX.US) and maintained its target price at $18. This indicates continued confidence in the company's stock from the financial firm.
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
RBC Capital analyst Leonid Timashev has maintained a Buy rating on Perspective Therapeutics (CATX), with the company's shares closing at $3.98. Timashev is a highly-rated analyst, and Piper Sandler also issued a Buy rating, though Bank of America Securities reiterated a Hold rating earlier. The company reported a reduced quarterly GAAP net loss of $37.49 million, down from $40.17 million the previous year.
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Perspective Therapeutics (CATX). This rating aligns with Piper Sandler's Buy rating, though Bank of America Securities reiterated a Hold rating. The company reported a GAAP net loss of $37.49 million for the quarter ending December 31.
Perspective Therapeutics (CATX) Receives a Buy from Piper Sandler
Piper Sandler analyst Biren Amin maintained a Buy rating on Perspective Therapeutics (CATX) with a $16.00 price target. This follows a similar Buy rating from Truist Financial, while Bank of America Securities reiterated a Hold rating. The company reported a GAAP net loss of $37.49 million for the quarter ending December 31.
Perspective Therapeutics (CATX) unveils 212Pb theranostic pipeline and manufacturing strategy
Perspective Therapeutics (CATX) has released an analyst presentation detailing its 212Pb-based theranostic pipeline and manufacturing strategy for targeted oncology. The presentation covers its VMT-α-NET program for neuroendocrine tumors and meningioma, highlighting clinical data, a regional manufacturing model for direct-to-hospital delivery, and unaudited financial estimates as of March 31, 2026. This announcement, made via an 8-K filing, outlines the company's approach to expanding market reach and optimizing production of its radiopharmaceutical products.
BlackRock stake in Perspective Therapeutics (CATX): 5.25M shares
BlackRock, Inc. has reported beneficial ownership of 5,251,363 shares of Perspective Therapeutics Inc. (CATX) common stock, which represents 4.6% of the class. This information was disclosed in an Amendment No. 1 to Schedule 13G/A, signed on April 27, 2026. BlackRock holds sole voting power for 5,189,434 shares and sole dispositive power for all 5,251,363 shares.
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
Perspective Therapeutics, a radiopharmaceutical development company, announced several upcoming corporate updates for May 2026, including an analyst event on its strategy and pipeline, the release of its Q1 2026 financial results, and fireside chats at the BofA Securities Health Care Conference and the RBC Capital Markets Global Healthcare Conference. The company specializes in advanced treatments for cancer using the alpha-emitting isotope 212 Pb and is developing complementary imaging diagnostics.
Perspective Therapeutics maps out May updates, Q1 results on May 11
Perspective Therapeutics (CATX) announced a series of corporate updates and investor events for May 2026. These include an analyst event on May 4, a Q1 2026 financial results press release on May 11, and fireside chats at the BofA Securities Health Care Conference on May 13 and the RBC Capital Markets Global Healthcare Conference on May 19. The company, a radiopharmaceutical developer, will post webcasts of these events on its website.
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR)
This article highlights two healthcare stocks, Perspective Therapeutics (CATX) and Nektar Therapeutics (NKTR), that have received bullish sentiments from analysts. JonesTrading reiterated a Buy rating on Perspective Therapeutics with an $18 price target, while William Blair reiterated a Buy rating on Nektar Therapeutics. Both companies have an analyst consensus of Strong Buy, with significant implied upsides based on current price targets.
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18
JonesTrading has reiterated its Buy rating for Perspective Therapeutics (CATX.US) and maintained its price target at $18. This indicates continued confidence from the firm in the company's performance and future prospects.
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the 2026 AACR Annual Meeting. The data shows continued strong anti-tumor activity in a significant portion of patients, with new responses and deepening of existing responses observed. The treatment, targeting SSTR2, continues to demonstrate a favorable safety profile across all dose cohorts.
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap Up - Should You Buy?
Perspective Therapeutics (CATX) shares gapped up to $4.58 from a $4.20 close, with analysts maintaining a "Buy" consensus and an average target of $12.63. The company, an early-stage biotech focused on targeted alpha therapies, is facing negative EPS despite strong liquidity. Several institutional investors have adjusted their holdings in CATX.
Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial for cancer. The company specializes in radiopharmaceutical development, using the alpha-emitting isotope 212Pb for targeted cancer treatment and imaging diagnostics. This update follows several recent analyst rating adjustments and financial reports for the company.
Perspective Therapeutics reports interim trial results for NET therapy
Perspective Therapeutics announced positive interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors, showing a 43% objective response rate in one cohort with no dose-limiting toxicities. The company's stock has surged, though InvestingPro analysis suggests it might be overvalued. Analysts have revised earnings estimates upward, and the company maintains a strong financial position, with more data expected later this year.
Early tumor trial: 43% responded, 72% stayed alive without progression
Perspective Therapeutics announced updated interim Phase 1/2a clinical trial data for their radiopharmaceutical [212Pb]VMT-α-NET in neuroendocrine tumors at the 2026 AACR Annual Meeting. The results showed a 43% objective response rate in Cohort 2 patients and 72% of patients remaining progression-free or alive. The company reported no dose-limiting toxicities or Grade 5 events among 64 treated patients, indicating a favorable safety profile to date.
Perspective Therapeutics posts updated Phase 1/2a [212Pb]VMT-α-NET data showing 43% response in Cohort 2
Perspective Therapeutics announced updated interim Phase 1/2a data for [212Pb]VMT-α-NET, showing a 43% investigator-assessed response rate in Cohort 2 patients and continued favorable tolerability. Key highlights include no dose-limiting toxicities or severe adverse events among 64 treated patients, and 72% of patients in early cohorts were progression-free. Additional data from later cohorts are anticipated to inform future regulatory filings and conferences.
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR)
JonesTrading and Piper Sandler analysts have reiterated Buy ratings for Perspective Therapeutics (CATX), citing a strong consensus price target of $13.50 with a significant upside. Similarly, William Blair and H.C. Wainwright maintained Buy ratings for Nektar Therapeutics (NKTR), projecting a consensus price target of $127.57. These reports indicate bullish sentiments for both companies within the Healthcare sector.
EBITDA per share of Perspective Therapeutics, Inc. – FWB:AAJ0
This page from TradingView provides financial information specifically focusing on the EBITDA per share for Perspective Therapeutics, Inc. (FWB:AAJ0), listed on the Frankfurt Stock Exchange. It indicates that the market is currently closed with no trades. The article also mentions the various data providers and copyright information.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received an average "Buy" rating from nine brokerages, with an average 12-month target price of $12.63. Institutional investors hold 54.66% of the company's stock, with several major firms increasing their stakes. Despite strong liquidity, the company is currently unprofitable, reporting a negative net margin and a forecast of -$0.88 EPS for the current fiscal year.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Increase in Short Interest
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) experienced a significant 39.9% increase in short interest during March, reaching 14,123,380 shares, accounting for 12.9% of its stock. Despite weak fundamentals, the company holds a consensus "Buy" rating and a mean price target of $12.63 from analysts. Institutional investors have notably adjusted their positions, with several increasing their stakes in the company.
JPMorgan Chase & Co. Sells 311,710 Shares of Perspective Therapeutics, Inc. $CATX
JPMorgan Chase & Co. decreased its stake in Perspective Therapeutics, Inc. by 41.7% in the third quarter, selling 311,710 shares. Despite this, other institutions like Vanguard Group, Geode Capital Management, Bank of America, UBS Group, and Patient Square Capital either increased or initiated positions, resulting in 54.66% institutional ownership. Analysts maintain a "Buy" rating with an average price target of $12.63, significantly higher than the current trading price of $4.37, even though the company reported a recent quarterly EPS of -$0.51 on minimal revenue.
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX)
This article provides a detailed overview of PERSPECTIVE THERAPEUTICS INC (CATX) stock, including its current price, performance metrics, key statistics, and technical and fundamental ratings from ChartMill. It also covers earnings reports, analyst forecasts, financial highlights, ownership details, and a company profile outlining its focus on medical technology and radiopharmaceuticals for cancer treatment. With a current stock price of $4.47, CATX has shown significant yearly growth but modest recent decline, and analysts anticipate substantial price appreciation.
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) announced its senior leadership team will participate in two upcoming investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium in Boston on April 16, 2026. The company, a radiopharmaceutical developer, will be available for one-on-one meetings with investors at these virtual and in-person events. Perspective Therapeutics is advancing treatments for various cancers using an alpha-emitting isotope and a "theranostic" approach.
Perspective Therapeutics lines up Needham, Piper investor meetings
Perspective Therapeutics (NYSE AMERICAN: CATX) announced that its senior leadership will participate in investor events in April 2026. This includes a presentation and fireside chat at the Needham Virtual Healthcare Conference on April 14, 2026, and one-on-one meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston. The company, a radiopharmaceutical development firm, will discuss its advanced treatments for cancers and corporate strategy.
Perspective Therapeutics to Participate in Upcoming Investor Conferences
Perspective Therapeutics, Inc. announced that its senior leadership will attend two upcoming investor conferences in April 2026. The company will participate in the 25th Annual Needham Virtual Healthcare Conference on April 14th and the Piper Sandler Spring Biopharma Symposium on April 16th for one-on-one meetings. Perspective Therapeutics is a radiopharmaceutical development company focused on advanced cancer treatments using its proprietary alpha-emitting isotope 212 Pb technology.
